1. Home
  2. CGEM vs AIV Comparison

CGEM vs AIV Comparison

Compare CGEM & AIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$16.18

Market Cap

904.7M

Sector

Health Care

ML Signal

HOLD

Logo Apartment Investment and Management Company

AIV

Apartment Investment and Management Company

HOLD

Current Price

$4.26

Market Cap

837.1M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGEM
AIV
Founded
2016
1975
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
904.7M
837.1M
IPO Year
2020
1996

Fundamental Metrics

Financial Performance
Metric
CGEM
AIV
Price
$16.18
$4.26
Analyst Decision
Strong Buy
Buy
Analyst Count
8
1
Target Price
$30.13
$10.00
AVG Volume (30 Days)
778.1K
1.3M
Earning Date
05-11-2026
05-06-2026
Dividend Yield
N/A
87.41%
EPS Growth
N/A
616.00
EPS
N/A
N/A
Revenue
N/A
$138,486,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$5.20
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.68
$3.94
52 Week High
$16.74
$8.87

Technical Indicators

Market Signals
Indicator
CGEM
AIV
Relative Strength Index (RSI) 65.46 48.27
Support Level $11.92 $4.03
Resistance Level N/A $4.28
Average True Range (ATR) 1.02 0.06
MACD 0.27 0.01
Stochastic Oscillator 92.55 33.33

Price Performance

Historical Comparison
CGEM
AIV

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

About AIV Apartment Investment and Management Company

Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment; Operating, and Other. Development and Redevelopment segment consists of properties that are under construction or have not achieved stabilization, as well as land held for development. Operating segment includes 20 residential apartment communities with 5,243 apartment homes that have achieved a stabilized level of operations. Other segment includes The Benson Hotel, company's only hotel. Majority of revenue is gained from Operating Segment.

Share on Social Networks: